Skip to main content

Table 1 Demographics, clinical characteristics, and CSF biomarker characteristics in DLB, AD, and controls

From: Amyloid-β peptides in cerebrospinal fluid of patients with dementia with Lewy bodies

 

DLB (n = 72)

AD (n = 38)

Controls (n = 38)

Female (n, %)

7 (10%)

3 (8%)

5 (13%)

Age (mean ± SD)

68 ± 6

68 ± 6

67 ± 6

MMSE (median [IQR])

23 [21–26]b

22 [18–25]b

29 [28–30]

APOEε4 carrier (n, %)

39 (57%)a

26 (72%)a

12 (32%)

CSF AD biomarkers Innotest (median [IQR])

 Aβ1-42 (pg/ml)*

790 [638–1040]b,d

620 [562–660]b

1123 [1022–1291]

 t-tau (pg/ml)

306 [228–368]b,d

611 [498–791]b

230 [187–271]

 p-tau (pg/ml)

47 [35–60]d

79 [65–99]b

44 [34–50]

 CSF tau/Aβ42 > 0.52 (n, %)

23 (33%)b,d

38 (100%)b

0 (0%)

CSF Aβ peptides MSD (mean ± SD)

 Aβ42 (pg/ml)

441 ± 185b,d

304 ± 71b

692 ± 205

 Aβ40 (pg/ml)

5432 ± 1340a

5897 ± 1066

6243 ± 1500

 Aβ38 (pg/ml)

2247 ± 638a,c

2524 ± 547

2676 ± 703

 Aβ42/Aβ40 ratio

0.08 ± 0.03b,d

0.05 ± 0.01b

0.11 ± 0.02

 Aβ42/Aβ38 ratio

0.20 ± 0.07b,d

0.12 ± 0.03b

0.26 ± 0.04

 Aβ38/Aβ40 ratio

0.41 ± 0.03a,c

0.43 ± 0.04

0.43 ± 0.02

  1. Data are presented as mean ± SD, median [interquartile range], or n (%). Differences between groups were assessed with ANOVA, χ2, and Kruskal-Wallis H tests where appropriate. For CSFAβ peptides, differences between diagnostic groups were assessed using ANOVA corrected for multiple comparisons using a false discovery rate (FDR) correction
  2. Abbreviations: Aβ42 amyloid β1-42 determined with MSD ELISA assay, Aβ40 amyloid β1-40 determined with MSD ELISA assay, Aβ38 amyloid β1-38 determined with MSD ELISA assay, AD Alzheimer’s disease, DLB dementia with Lewy bodies, MMSE mini-mental state examination, MSD Meso Scale Discovery
  3. ap < 0.05 compared to controls; bp < 0.001 compared to controls; cp < 0.05 compared to AD; dp < 0.001 compared to AD
  4. *Levels of Innotest Aβ1-42 were drift corrected [28]